Outlook Therapeutics (NASDAQ:OTLK) Trading 9.7% Higher

Share on StockTwits

Outlook Therapeutics, Inc. (NASDAQ:OTLK)’s stock price traded up 9.7% during trading on Friday . The stock traded as high as $1.32 and last traded at $1.24, 1,504,693 shares were traded during mid-day trading. A decline of 8% from the average session volume of 1,632,410 shares. The stock had previously closed at $1.13.

Several equities analysts have commented on the stock. Zacks Investment Research downgraded shares of Outlook Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 6th. LADENBURG THALM/SH SH assumed coverage on shares of Outlook Therapeutics in a research note on Wednesday, September 11th. They issued a “buy” rating and a $9.00 price target for the company. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Outlook Therapeutics currently has an average rating of “Buy” and an average target price of $7.79.

The company’s 50 day simple moving average is $1.16 and its 200 day simple moving average is $1.72. The firm has a market cap of $31.90 million, a price-to-earnings ratio of -0.11 and a beta of -0.75.

Several large investors have recently bought and sold shares of OTLK. Cormorant Asset Management LP acquired a new position in shares of Outlook Therapeutics during the second quarter worth $32,000. Virtu Financial LLC acquired a new position in shares of Outlook Therapeutics during the third quarter worth $83,000. LVW Advisors LLC grew its stake in shares of Outlook Therapeutics by 37.6% during the third quarter. LVW Advisors LLC now owns 389,088 shares of the company’s stock worth $580,000 after purchasing an additional 106,293 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Outlook Therapeutics by 712.1% during the second quarter. Vanguard Group Inc. now owns 396,001 shares of the company’s stock worth $824,000 after purchasing an additional 347,238 shares in the last quarter. Institutional investors and hedge funds own 3.35% of the company’s stock.

Outlook Therapeutics Company Profile (NASDAQ:OTLK)

Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.

Featured Article: What is meant by holder of record?

Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Abbott Laboratories  Updates Q1 2020
Pre-Market Earnings Guidance
Abbott Laboratories Updates Q1 2020 Pre-Market Earnings Guidance
Express  Issues Q4 2019
Pre-Market Earnings Guidance
Express Issues Q4 2019 Pre-Market Earnings Guidance
Applied Industrial Technologies  Releases FY20 Earnings Guidance
Applied Industrial Technologies Releases FY20 Earnings Guidance
Janney Montgomery Scott LLC Purchases 22,288 Shares of Colgate-Palmolive
Janney Montgomery Scott LLC Purchases 22,288 Shares of Colgate-Palmolive
Janney Montgomery Scott LLC Boosts Stake in Vanguard Large-Cap ETF
Janney Montgomery Scott LLC Boosts Stake in Vanguard Large-Cap ETF
Janney Montgomery Scott LLC Trims Stock Position in Emerson Electric Co.
Janney Montgomery Scott LLC Trims Stock Position in Emerson Electric Co.


© 2006-2020 Ticker Report